GSK sees LifeMine as a fungi to be around

23 March 2022

LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), has announced the completion of a $175 million Series C financing.

The round was led by new investor Fidelity Management & Research Company, with participation by additional newcomers Invus and 3W Partners Capital, while UK pharma major GlaxoSmithKline (LSE: GSK) also joined the financing as a strategic partner.

"Together we can identify what nature might have already created"Existing investors, including GV, Arch Venture Partners, Blue Pool Capital and MRL Ventures Fund, also participated in the round, which takes LifeMine’s fundraising in total beyond $295 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK